製品名:3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole

IUPAC Name:3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole

CAS番号:1429558-08-6
分子式:C9H12N6S
純度:95%+
カタログ番号:CM1044501
分子量:236.3

包装単位 有効在庫 価格(USD) 数量

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1429558-08-6
分子式:C9H12N6S
融点:-
SMILESコード:C[C@H]1NCCN2C1=NN=C2C1=NC(C)=NS1
密度:
カタログ番号:CM1044501
分子量:236.3
沸点:
MDL番号:
保管方法:

Category Infos

Thiadiazoles
Thiadiazoles are a subfamily of azoles. Structurally, they are five-membered heterocyclic compounds containing two nitrogen atoms and one sulfur atom, and two double bonds, forming an aromatic ring. Depending on the relative positions of the heteroatoms, there are four possible structures; these forms do not interconvert and are therefore structural isomers rather than tautomers. These compounds themselves are rarely synthesized and have no particular utility, however, compounds that use them as structural motifs are fairly common in pharmacology.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products